JAK1 and COVID-19: Taken together with phase 3 studies of the JAK1/JAK2 inhibitor baricitinib [12, 13, 14] and ruxolitinib studies [10, 11, 15], this EAP suggests that ruxolitinib may offer clinical status improvements for some patients with the most severe manifestations of COVID‐19.